James B. Kaper is a Professor and Chair of the Department of Microbiology & Immunology at the University of Maryland School of Medicine. He serves as Vice Dean for Academic Affairs and previously held leadership roles as Senior Associate Dean (2014–2019) and Chair (2007–present). His research focuses on the molecular pathogenesis of diarrheagenic Escherichia coli and Vibrio cholerae , including vaccine development and bacterial-host interactions. Education: BS (1973) and PhD (1979) in Microbiology from University of Maryland; Postdoc in Molecular Pathogenesis at University of Washington (1979–1981) Dr. Kaper’s work has led to the creation of live attenuated cholera vaccines, including CVD 103-HgR, the first licensed recombinant bacterial vaccine. His lab investigates bacterial genetics, intestinal colonization, and immune system activation, particularly TLR5 response to V. cholerae flagellin. He has authored 303 peer-reviewed articles and 68 book chapters. His research has been funded continuously by NIAID since 1982. Key publications include foundational work on V. cholerae vaccines (1984), genomic structure (1998), and quorum sensing in EHEC/EPEC (1999). His lab’s recent studies focus on phosphotyrosine proteomics (2013) and pathogenicity island regulation (2007). Scientific awards: Fellow, American Academy of Microbiology (1994); NIH Merit Award (2004); ASM DC White Award (2019) Editorial roles: Editor-in-Chief, EcoSal (2006–present); Associate Editor, International Journal of Medical Microbiology (2000–present) As an academic leader, Dr. Kaper has mentored over 60 graduate students and postdoctoral fellows. He holds multiple patents for cholera vaccines and E. coli diagnostics, including U.S. Patents 4,935,364; 5,399,494; and 6,204,004. His lab at UMSOM combines basic science with translational applications for enteric disease prevention.
Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.
Thibault Mayor is a Professor in the Department of Biochemistry and Molecular Biology and the Michael Smith Laboratories at the University of British Columbia (Vancouver). His research focuses on understanding how cells manage misfolded proteins, with implications for neurodegenerative diseases like Parkinson's and Alzheimer's. He holds academic affiliations with the Centre for High-Throughput Biology (CHiBi) and has been recognized with awards including the UBC Killam Teaching Award (2020). Education: BSc, University of Geneva, Switzerland (1997) PhD, University of Geneva & Max Planck Institute of Biochemistry, Germany (2001) Postdoctoral Fellow, California Institute of Technology (2002) Research Interests: Mayor's lab investigates protein homeostasis, ubiquitin-proteasome system dynamics, and the molecular mechanisms underlying protein aggregation in aging and disease. Projects include proteomic approaches to identify aggregation-prone proteins and develop microbial cell factories for protein production. Grants & Awards: CIHR Project Grant ($730K, 2018) Michael Smith Foundation Career Award (2012) UBC Killam Teaching Award (2020) Labs & Collaborations: The Mayor Lab is part of the Michael Smith Laboratories and collaborates with computational biologists like Jörg Gsponer. They maintain active partnerships in proteomics and systems biology, contributing to initiatives like the BC Proteomics Network.
Tracey Evans Chan is an Associate Professor and Director of the NUS Law Academy at the National University of Singapore's Faculty of Law. His expertise lies in biomedical law and ethics, with a focus on issues such as surrogacy, transplant ethics, and human-animal research. He has held significant roles, including a secondment to Singapore's Ministry of Health, where he contributed to the Human Biomedical Research Act 2015. He currently serves on the National Medical Ethics Committee and the Advisory Committee on Restricted Research under the same Act, and is a member of NUS's Institutional Review Board. Education: LLM (Harvard University) LLB (National University of Singapore) Research Interests: Chan's work bridges legal and ethical dimensions of biomedical advancements. Key areas include regulatory challenges in mitochondrial replacement technology, consent frameworks for minors, and the ethical implications of emerging medical technologies. His contributions to Singapore's legal committees reflect his commitment to balancing innovation with societal values. Publications & Trends: His recent works explore themes like advance care planning, the placebo effect in clinical practice, and cross-jurisdictional comparisons of healthcare dependency laws. These publications underscore his interdisciplinary approach to legal and biomedical challenges. Awards & Grants: No specific awards or grants are listed, but his policy contributions and academic output highlight his impactful work in regulatory frameworks. Advising & Teams: As a faculty member, he teaches courses like Medical Law and Ethics. His involvement in NUS's Institutional Review Board and Singapore's advisory committees demonstrates his role in shaping research ethics and healthcare policy.
Chang-Jun Liu is a Senior Scientist in the Plant Science Group of the Biology Department at Brookhaven National Laboratory, where he has conducted research on plant phenylpropanoid biosynthesis and lignin metabolism since joining in 2005. He also holds an Adjunct Professor position in the Biochemistry & Cell Biology Department at Stony Brook University and serves as Associate Editor for Plant Cell & Environment (2024-present) and Frontiers in Plant Sciences (2015-present). Dr. Liu's educational background includes: Ph.D. in Plant Biochemistry and Molecular Biology from the Shanghai Institute of Plant Physiology, Chinese Academy of Science (1999) Dr. Liu's research integrates approaches from biochemistry, molecular genetics, biophysics, protein engineering, metabolic engineering, and synthetic biology to investigate phenylpropanoid and lignin biosynthesis in plants. His laboratory addresses fundamental questions about how lignin and related compounds are synthesized and incorporated into cell walls, how regulatory networks govern metabolic activity, and how lignification influences cell wall structure and function. A central aim of his research is optimizing plant feedstocks for efficient lignocellulosic biomass utilization. Analysis of Dr. Liu's publication record reveals a consistent trajectory from fundamental biochemical mechanisms to applied bioenergy solutions. His recent work focuses on cytochrome b5 diversity, electron transfer mechanisms in phenolic biosynthesis, and metabolic engineering approaches to modify lignin composition. This research spans from evolutionary studies of lignin biosynthesis across plant lineages to practical applications in bioenergy crop improvement. Dr. Liu has received recognition for his contributions to science, including: Brookhaven National Laboratory Science and Technology Award (2018) Dr. Liu serves as Editorial Board Member for the Journal of Biological Chemistry (2020-present), PNAS Nexus (2024-present), and Plant Physiology Journal (2025-). He is Scientific Lead at the Joint BioEnergy Institute, Feedstocks Division, Lawrence Berkeley National Laboratory, and Project Lead at the Center for Bioenergy Innovation, Oak Ridge National Laboratory. His research is funded by the U.S. Department of Energy through multiple Bioenergy Research Centers. Dr. Liu leads a research group at Brookhaven National Laboratory focused on elucidating the posttranslational regulation and macromolecular organization of lignin biosynthesis, with applications toward developing designer lignins and reducing biomass recalcitrance for sustainable biofuel production. His work addresses the critical challenge of lignin's dual nature: while it impedes enzymatic access to polysaccharides in biofuel production, it also represents the most abundant renewable source of aromatic carbon for high-value bioproducts.
Dewey G. McCafferty is Professor of Chemistry at Duke University with appointments in Biochemistry and the Duke Cancer Institute. His research focuses on chemical biology of chromatin-modifying enzymes and ubiquitin signaling pathways relevant to neurodegeneration and infection. Notable work includes discovering the lasso peptide antibiotic Arcumycin, characterizing the Nedd4 ubiquitin ligase in Parkinson's disease models, and developing chemoproteomic approaches for target identification. Key contributions include elucidation of the futalosine pathway in Chlamydia infections, mechanisms of CPAF protease in bacterial pathogenesis, and engineering of histone demethylase enzymes. McCafferty received the Eli Lilly Award in Biological Chemistry (2005) and directs NIH-funded projects on ubiquitin ligases in neurodegeneration.
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
Professor John Pickett serves as Chair of the School of Chemistry at Cardiff University, where he holds the position of Professor of Biological Chemistry. His research program has established him as a leading figure in chemical ecology with significant contributions to understanding chemically mediated interactions between organisms. Professor Pickett's research focuses on chemical ecology involving chemically mediated interactions between various organisms, particularly pests attacking plants and animals. His work encompasses the chemical characterisation of pheromones and other semiochemicals across plants and animals, including insect pests and beneficial organisms. He investigates stress-related chemical signalling by plants and vertebrates (including humans and farm animals), elucidates biosynthetic pathways to pheromones and other semiochemicals, and explores how these compounds can be exploited in pest management through ecological approaches and genetic modification. Analysis of Professor Pickett's recent publications reveals a sustained and impactful research trajectory spanning chemical ecology, agricultural science, and sustainable development. His work demonstrates remarkable continuity in investigating semiochemicals and pheromones while expanding into interdisciplinary areas including AI applications for sustainable futures and the economic impacts of agricultural innovations. A consistent theme throughout his career is the practical application of chemical ecology principles to develop sustainable pest management solutions, particularly through the development and refinement of push-pull farming systems that have transformed agricultural practices in Africa.
Furkan Alaca is an Assistant Professor at Queen's University's School of Computing, part of the Faculty of Arts and Science. His research focuses on user authentication systems, addressing security and usability challenges. He holds a Ph.D. (2018) in Computer Science from Carleton University, an M.A.Sc. (2012) in Electrical and Computer Engineering, and a B.Eng. (2010) in Communications Engineering, all from Carleton University. His academic career includes teaching roles at Queen's University and the University of Toronto Mississauga, where he taught courses such as Cryptography, Cybersecurity, and Discrete Mathematics. He is affiliated with Queen's Security Research Group and Computer Security Research Lab. Research interests include computer and internet security, usable security, authentication mechanisms, and systems security. He has contributed to advancements in web authentication frameworks, malware analysis, and privacy-preserving technologies. His work spans conferences like IEEE and ACM, with notable publications in cybersecurity, machine learning, and network efficiency. Current teaching includes CISC 447 (Introduction to Cybersecurity) and CISC 468 (Cryptography). He has advised on courses ranging from undergraduate programming to graduate-level security topics.
Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models
Aditi Das is a Full Professor in the School of Chemistry and Biochemistry at the Georgia Institute of Technology, College of Sciences. She leads the Das Laboratory, which focuses on the biochemistry and chemical biology of lipids, particularly studying cytochrome P450 enzymes and their role in lipid metabolism, endocannabinoid systems, and inflammatory pathways. Her educational background includes: B.Sc. in Chemistry from St. Stephen's College M.Sc. in Chemistry from Indian Institute of Technology, Kanpur (I.I.T) Ph.D. in Chemistry from Princeton University Postdoctoral research at Northwestern University (NSF-NSEC fellow) and Beckman Institute for Advanced Science and Technology, University of Illinois UC Professor Das's research interests center around understanding the physiological role of lipids in sustaining homeostasis and their implications in disease states such as neurodegenerative disorders, cancer, and cardiovascular diseases. Her laboratory specializes in: Enzymology of cytochrome P450s, particularly CYP2J2 epoxygenase Metabolism of ω-3 and ω-6 fatty acids and their derivatives Minor cannabinoid metabolism by cytochrome P450 enzymes Discovery of novel anti-inflammatory lipid metabolites and endocannabinoids Mechanistic studies of membrane proteins using nanodisc technology Her work bridges biochemistry, chemical biology, and pharmacology to uncover novel therapeutic targets related to lipid signaling pathways. Analysis of Professor Das's recent publications (2023-2025) reveals a strong focus on cannabinoid metabolism by cytochrome P450 enzymes, with particular emphasis on how these metabolic processes generate bioactive compounds that interact with the endocannabinoid system. Her research increasingly explores the therapeutic potential of omega-3 derived endocannabinoid epoxides in inflammatory and neurodegenerative conditions. The use of nanodisc technology for studying membrane proteins in near-native environments remains a consistent methodological thread throughout her work, enabling detailed mechanistic insights into enzyme function. Professor Das has received numerous prestigious awards recognizing her research excellence and teaching: 2024 NIH Outstanding Researcher Award (MIRA R35) for established investigators 2024 Vasser Woolley Faculty Fellowship 2023 Plenary Lecture at the International Society of the Study of Xenobiotics (ISSX) 2021 E.L.R. Stokstad Award 2019-2021 List of Teachers Ranked as Excellent 2019 Eicosanoid Research Foundation Young Investigator Award 2019 Zoetis Research Excellence Award 2019 Mary Swartz Rose Young Investigator Award 2015 National Scientist Development Award from the American Heart Association 2022 El Sohly Award from the American Chemical Society Professor Das actively mentors a diverse group of students and postdoctoral researchers, with several former lab members now holding faculty positions or working at prestigious institutions. Her laboratory has secured significant funding from NIH, NSF, and other sources to support research on lipid metabolism, cannabinoid pharmacology, and membrane protein biochemistry. Notable grants include an NIH R35 Outstanding Investigator Award (MIRA), an NIH R21 grant from NIDA, and multiple collaborative grants with other research groups. The Das Laboratory operates within the Petit Institute of Bioengineering and Biosciences (IBB) at Georgia Tech, utilizing state-of-the-art facilities for biochemical and biophysical studies. The lab specializes in nanodisc technology to study membrane proteins in near-native environments, with particular expertise in cytochrome P450 enzymes and their interactions with lipid substrates. Recent work has expanded into collaborative projects involving lipidomics, structural biology, and translational applications of lipid signaling research.
Christopher E. Nelson is an Assistant Professor in the Department of Biomedical Engineering at the University of Arkansas, College of Engineering. His lab focuses on developing biologically inspired strategies for controlled drug and gene delivery, particularly in the context of gene therapy and regenerative medicine. He is actively supported by the NIH, DoD, and Arkansas Bioscience Institute. Education: Postdoctoral Fellow – Duke University Ph.D. – Vanderbilt University B.S. – University of Arkansas Research Focus: Dr. Nelson’s lab integrates genome editing technologies with targeted delivery systems to address challenges in treating genetic diseases and promoting tissue regeneration. Major themes include CRISPR/Cas9 delivery , gene regulation in wound healing , and safe-harbor genome integration in skeletal muscle. His work spans viral and non-viral delivery vehicles , including lipid nanoparticles and AAV vectors, with a strong emphasis on preclinical validation in models of Duchenne muscular dystrophy and inflammatory disease. Scientific Awards: Controlled Release Society Postdoctoral Fellowship The Hartwell Foundation Postdoctoral Fellowship NIH Pathway to Independence Award (K99/R00) Funding & Support: The Nelson Lab is currently funded by: NIH NIGMS R35 DoD CDMRP DMD IDEA Award Arkansas Bioscience Institute University of Arkansas Engineering & Honors Colleges Lab & Team: The Nelson Lab is a dynamic, interdisciplinary team working at the intersection of gene editing, biomaterials, and regenerative medicine. They regularly present at national conferences such as ASGCT and NCUR, and mentor undergraduate researchers through SURF and Honors College grants.
Laura Solt, Ph.D. is an Associate Professor in the Department of Immunology and Microbiology at the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida. She also serves as Associate Dean of the Skaggs Graduate School of Chemical and Biological Sciences. Dr. Solt began her independent research career at Scripps Florida in 2013 and has established herself as a leading researcher in nuclear receptor biology within the immune system. Her research focuses on understanding the biologically relevant roles of nuclear receptors, particularly RORα and REV-ERBs, in the immune system with emphasis on TH17 cell development and autoimmune disease. Her lab employs a multidisciplinary approach combining molecular biology, genetic techniques, and chemical biology coupled with mouse models of autoimmunity and chronic inflammation. Dr. Solt's laboratory has made significant contributions to understanding how nuclear receptors regulate immune cell function, particularly in TH17-mediated inflammation. Her work has demonstrated roles for RORα and REV-ERBs in TH17 cell development and has developed synthetic ligands to these receptors for potential therapeutic applications in autoimmune diseases. Her extensive publication record shows a clear trajectory of research focused on nuclear receptor signaling in immunity, with recent work expanding into applications for cancer immunotherapy, neuroimmunology, and metabolic aspects of immune cell function. Her articles demonstrate expertise in both basic nuclear receptor mechanisms and translational applications. Ruth L. Kirschstein National Research Service Awards (2010-2013) Dr. Solt actively mentors graduate students including Adrianna Wilson (recipient of NIDDK F31 and Scheller Graduate Student Fellowship) and Sarah Mosure (recipient of NIH NRSA F31 award and Wendy Havran award). Her laboratory receives substantial funding from multiple NIH institutes (NIDDK, NCI, NIAID, NIGMS) as well as the Crohn's & Colitis Foundation. Current research directions include investigating the roles of NR2F6 in TH17 cells, exploring RORα function in CD8 T cells, and developing novel nuclear receptor modulators for therapeutic applications.
